Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Neurogranin antisense RNA 1 (NRGN-AS1)
- Target
- NRGN-AS1
- Molecular classification
- Long non-coding RNA (lncRNA), Antisense RNA, Noncoding antisense transcript (NAT)
01
Overview
Neurogranin antisense RNA 1 (NRGN-AS1) is a long non-coding antisense RNA transcribed from the locus of the Neurogranin (NRGN) gene, implicated through sequence complementarity in the regulation of NRGN expression. Like other antisense lncRNAs, NRGN-AS1 may modulate gene expression at transcriptional or post-transcriptional levels, potentially influencing chromatin modification, mRNA stability, and alternative splicing. There is increasing evidence that antisense RNAs play regulatory roles in neurodevelopment and disease; however, the specific biological functions and disease links of NRGN-AS1 are yet to be fully characterized. Antisense lncRNAs as a group are broadly associated with epigenetic regulation, imprinted gene silencing, and disease mechanisms such as cancer and neurodegeneration, though direct links for NRGN-AS1 itself remain limited to genomic and transcriptomic description.
- Other names
- RP11-677M14.2Nrgn-ASNRGN-AS1
02
Mechanism of action
Not applicable. No drugs or clinical interventions are known to act specifically via NRGN-AS1.
03
Biological functions
Regulation of gene expression via antisense RNA mechanisms (cis and trans)Potential modulation of chromatin structure and transcriptional regulationPossible influence on neurogranin mRNA stability or translation, though specific mechanisms for NRGN-AS1 remain to be firmly elucidated
04
Disease associations
Potential role in neurodegenerative diseases (by analogy to other antisense lncRNAs)May be involved in cancer or epigenetic dysregulation, as dysregulation of NATs is frequent in cancersSpecific disease associations for NRGN-AS1 itself have not been extensively validated
05
Safety considerations
None reported. AS-lncRNAs as a class pose technical challenges for therapeutic targeting and for the risk of off-target or epigenetic effects, but no specific safety issues have been attributed to NRGN-AS1 itself
Beyond the preview
Go deeper on Neurogranin antisense RNA 1 (NRGN-AS1).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Neurogranin antisense RNA 1 (NRGN-AS1).